Business Context and Reporting Period
BioNTech SE filed Form 6-K for October 2021 under the Foreign Private Issuer reporting requirements. The filing was signed on October 18, 2021 and reports an October 15, 2021 announcement with Pfizer Inc. regarding COMIRNATY.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Developments
- BioNTech and Pfizer submitted data to the European Medicines Agency for a variation of COMIRNATY’s Conditional Marketing Authorization.
- The submission supports vaccination of children 5 to less than 12 years of age.
- The related press release was included as Exhibit 99.1.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, forecasts, management commentary on operating performance, risk disclosures, contingencies, or unusual financial items. The regulatory submission remains subject to EMA review and any applicable authorization decision.
Investor Verification Items
- Verify the data submitted to the EMA and the scope of the requested authorization variation.
- Monitor the EMA’s review and any subsequent regulatory decision for use in children 5 to less than 12 years of age.
- Review Exhibit 99.1 for additional clinical, regulatory, or safety information not reproduced in the filing cover document.